Nucleosides, Nucleotides, and Nucleic Acids, 26:713–716, 2007

ISSN: 1525-7770 print / 1532-2335 online
DOI: 10.1080/15257770701490852

Taylor & Francis
Taylor & Francis Group

SYNTHESIS AND ANTITUMOR ACTIVITY OF FLUOROCYCLOPENTENYL-PYRIMIDINES

Lak Shin Jeong, Long Xuan Zhao, Won Jun Choi, Shantanu Pal, Yeon Hee Park and Sang Kook Lee □ *College of Pharmacy, Ewha Womans University, Seoul, Korea*

Moon Woo Chun □ *College of Pharmacy, Seoul National University, Seoul, Korea*

Young B. Lee and Chang Ho Ahn □ *Rexahn Corporation, Rockville, Maryland, USA*

Hyung Ryong Moon □ *College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Korea*

□ *Synthesis of fluorocyclopentenyl pyrimidine nucleosides* **6–9** *was enantiopurely accomplished employing oxidative rearrangement, RCM reaction and electrophilic fluorination starting from* D-*ribose. Cytosine analog* **8** *was found to exhibit significant anticancer activity in various human tumor cell lines.*

Keywords Electrophilic fluorination; ring-closing metathesis; oxidative rearrangement; Mitsubobu condensation; antitumor

INTRODUCTION

Aristeromycin (**1**) and neplanocin A (**2**)[1,2] are representatives of the carbocyclic nucleosides with potent antiviral and antitumor activities (Figure 1). They act by the inhibition of *S*-adenosylhomocysteine (AdoHcy) hydrolase, an enzyme which catalyzes hydrolysis of AdoHcy into adenosine and L-homocysteine. AdoHcy hydrolase is considered a promising target in the development of new antiviral agents because inhibition of AdoHcy hydrolase induces the inhibition of methyltransferases, an enzyme necessary to process viral *m*-RNA.

On the other hand, cytidine analog **3** constructed on the basis of cyclopentenyl sugar ring of neplanocin A (**2**) has been reported to show

This research was supported by a grant from the Korea Research Foundation (KRF-2005-005-J01502).

Address correspondence to Lak Shin Jeong, College of Pharmacy, Ewha Womans University, Seoul 120-750, Korea. E-mail: lakjeong@ewha.ac.kr



FIGURE 1 Rationale for the design of fluorocyclopentenyl pyrimidine nucleosides, **6–9**.

potent antitumor activity by Marquez et al.[3] Recently, 5-fluorocytosine derivative **4** was reported to exhibit potent anti-West-Nile virus activity by Chu and coworkers.[4] More recently, fluoroneplanocin A (**5**),[5] designed and synthesized by us as an irreversible AdoHcy hydrolase inhibitor, has shown potent antiviral activity.

The above finding prompted us to synthesize a series of new fluoroneplanocin A (**5**) derivatives. In the present communication, we report a synthetic method for fluorocyclopentenyl pyrimidines **6–9** and their cytostatic activity in a variety of human tumor cells.

RESULTS AND DISCUSSION

The key intermediate **16** has been obtained from cyclopentenone **14**[6,7] starting from D-ribose (Scheme 1). Briefly, treatment of D-ribose with anhydrous acetone in the presence of concentrated sulfuric acid followed by reaction with TBDPSCl gave 2,3-isopropylidene-5-TBDPS-D-ribose (**10**). Wittig reaction of compound **10** with methylenephosphorane followed by Swern oxidation with oxalyl chloride and DMSO afforded ketone, which was subjected to a Grignard reaction with vinylmagnesium bromide to give diene **11** as a single diastereomer. Before ring-closing metathesis (RCM) reaction[8] of **11**, TBDPS group was replaced with benzyl group compatible with further synthetic procedures. TBDPS group of **11** was removed with TBAF and then one of hydroxyl functions in resulting diol system was regioselectively protected with benzyl group, after hydroxyl activation with dibutyltin oxide,



SCHEME 1 Reagents and conditions: a) acetone, c-H_2SO_4, 93%; b) TBDPSCl, imidazole, CH_2Cl_2, 99%; c) Ph_3PCH_3Br, KO*t*-Bu, THF, 93%; d) $(COCl)_2$, DMSO, CH_2Cl_2, -78°C, 1 hour, then Et_3N, rt, 1 hour, 98%; e) CH_2 =CHMgBr, THF, 84%; f) *n*-Bu_4NF, THF, 99%; g) $Bu_2Sn(O)$, toluene, 15 hours, then TBAI, BnBr, 75°C, 16 hour, 87%; hour) second generation Grubbs catalyst, CH_2Cl_2, 88%; i) PDC, 4 A MS, DMF, rt, 18 hour, 59%.

giving **12**. RCM reaction of diene **12** with second generation Grubbs catalyst followed by oxidative rearrangement of the resulting *tert*-allylic alcohol **13** with PDC in DMF gave the desired cyclopentenone **14**, which was a substrate for the synthesis of fluorocyclopentenol **16**.

Synthesis of fluorocyclopentenol **16** and the final pyrimidine nucleosides **6-9** is shown in Scheme 2. First, compound**14** was converted to glycosyl donor, fluorocyclopentenol **16** in a five-step reaction procedure. These included: iodination of **14** using I_2 and pyridine; stereo- and regioselective reduction of α,β-unsaturated ketone with $NaBH_4$ in the presence of cerium (III) ion; and protection of the resulting hydroxyl group with TBDPS, providing **15**. Electrophilic fluorination at vinyl position via metal-halogen exchange was accomplished by treating of compound **15** with *N*-fluorobenzenesulfonimide and *n*-BuLi to give fluorocyclopentenol **16** after desilylation with TBAF. Coupling of **16** with N^3-benzoyluracil and N^3-benzoyl-5-fluorouracil under Mitsunobu conditions followed by removal of benzoyl group with methanolic ammonia and benzyl group with BCl_3, provided uracil nucleoside **6** and 5-fluorouracil nucleoside **7**, respectively. Compound **6** and **7** were converted to cytosine nucleosides **8** and **9** according to the conventional method: i. Ac_2O, pyridine; ii. $POCl_3$, Et_3N, 1,2,4-triazole; iii. NH_4OH, 1,4-dioxane; iv. NH_3/MeOH.

The growth inhibition activity of all synthesized final nucleosides **6-9** in various human tumor cell lines was evaluated using the Sulforhodamine B method.[9] Among the tested compounds, cytosine analog **8** was the most active in a range of tumor cell lines. IC_{50} (μM) of **8** against human cancer cell lines are as follows: 0.34 in MCF-7 (breast, hormone-dependent), 0.18 in MDA-MB-231 (breast), 1.35 in HeLa (cervix), 0.80 in human OVCAR-3 (ovary), 2.67 in LNCap (prostate), 0.79 in HepG2 (liver), 0.50 in A549 (lung), 0.25 in NCI-H226 (lung), 0.28 in HT-29 (colon), 0.19 in HCT116 (colon), 1.38 in SK-MEL-28 (melanoma), 0.62 in PANC-1 (pancreas), 0.63 in PC (prostate), 0.83 in U251 (brain), 0.34 in MKN-45 (stomach), and 0.83 in UMRC2 (kidney).



SCHEME 2 Reagents and conditions: a) I_2, pyridine, CCl_4, 55%; b) $NaBH_4$, $CeCl_3$, 93%; c) TBDPSCl, imidazole, DMF, 97%; d) *N*-fluorobenzene-sulfonimide, *n*-BuLi, THF, - 78°C, 80%; e) *n*-Bu_4NF, THF, 80%; f) N^3-benzoyluracil or N^3-benzoyl-5-fluorouracil, DEAD, Ph_3P, THF, then NH_3/MeOH, 81%; g) BCl_3, CH_2Cl_2, 60%; hour) i. Ac_2.O, pyridine; ii. $POCl_3$, Et_3N, 1,2,4-triazole; iii. NH_4OH, 1,4-dioxane; iv. NH_3/MeOH, 40%.

In conclusion, fluorocyclopentenyl pyrimidine nucleosides **6–9** were designed and synthesized starting from D-ribose using stereoselective Grignard reaction, oxidative rearrangement, and electrophilic fluorination. Among the obtained compounds, cytidine analog **8** has shown the most potent cytostatic activity in variety of human cancer cell lines.

REFERENCES

1. Yaginuma, S.; Muto, N.; Tsujino, M.; Sudate, Y.; Hayashi, M.; Otani, M. Studies on neplanocin A, new antitumor antibiotic. I. Producing organism, isolation and characterization. *J. Antibiot.* **1981**, 34, 359–366.
2. Hayashi, M.; Yaginuma, S.; Yoshioka, H.; Nakatsu, K. Studies on neplanocin A, new antitumor antibiotic. II. Structure determination. *J. Antibiot. (Tokyo)* **1981**, 34, 675–680.
3. Marquez, V.E.; Lim, M.-I.; Treanor, S.P.; Plowman, J.; Priest, M.A.; Markovac, A.; Khan, M.S.; Kaskar, B.; Driscol, J.S. Cyclopentenylcytosine. A carbocyclic nucleosides with antitumor and antiviral properties. *J. Med. Chem.* **1988**, 31, 1687–1694.
4. Song, G.Y.; Paul, V.; Choo, H.; Morrey, J.; Sidwell, R.W.; Schinazi, R.F.; Chu, C.K. Enantiomeric synthesis of D- and L-cyclopentenyl nucleosides and their antiviral activity against HIV and West-Nile virus. *J. Med. Chem.* **2001**, 44, 3985–3993.
5. Jeong, L.S.; Yoo, S.J.; Lee, K.M.; Koo, M.J.; Choi, W.J.; Kim, H.O.; Moon, H.R.; Lee, M.Y.; Park, J.G.; Lee, S.K.; Chun, M.W. Design, synthesis, and biological evaluation of fluoroneplanocin A as the novel mechanism-based inhibitor of *S*-adenosylhomocysteine hydrolase. *J. Med. Chem.* **2003**, 46, 201–203.
6. Choi, W.J.; Moon, H.R.; Kim, H.O.; Yoo, B.N.; Lee, J.A.; Shin, D.H.; Jeong, L.S. Preparative and stereoselective synthesis of the versatile intermediate for carbocyclic nucleosides: Effects of the bulky protecting groups to enforce facial selectivity. *J. Org. Chem.* **2004**, 69, 2634–2636.
7. Moon, H.R.; Choi, W.J.; Kim, H.O.; Jeong, L.S. Preparative synthesis of the key intermediate (4*R*,5*R*)-3-Benzyloxymethyl-4,5-isopropylidenedioxycyclopent-2-enone for carbocyclic nucleosides. *Chem. Lett.* **2004**, 33, 506–507.
8. Grubbs, R.H.; Chang, S. Recent advances in olefin metathesis and its application in organic synthesis. *Tetrahedron* **1998**, 54, 4413–4450.
9. Lee, S.K.; Nam, K.-A.; Heo, Y.-H. Cytotoxic activity and G2/M cell cycle arrest mediated by antofine, A phenanthroindolizidine alkaloid isolated from cyanchum paniculatum. *Planta. Med.* **2003**, 69, 21–25.